Document Detail


Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
MedLine Citation:
PMID:  16705109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies.
OBJECTIVE: To assess the extent to which anti-TNF antibody therapies may increase the risk of serious infections and malignancies in patients with rheumatoid arthritis by performing a meta-analysis to derive estimates of sparse harmful events occurring in randomized trials of anti-TNF therapy.
DATA SOURCES: A systematic literature search of EMBASE, MEDLINE, Cochrane Library, and electronic abstract databases of the annual scientific meetings of both the European League Against Rheumatism and the American College of Rheumatology was conducted through December 2005. This search was complemented with interviews of the manufacturers of the 2 licensed anti-TNF antibodies.
STUDY SELECTION: We included randomized, placebo-controlled trials of the 2 licensed anti-TNF antibodies (infliximab and adalimumab) used for 12 weeks or more in patients with rheumatoid arthritis. Nine trials met our inclusion criteria, including 3493 patients who received anti-TNF antibody treatment and 1512 patients who received placebo.
DATA EXTRACTION: Data on study characteristics to assess study quality and intention-to-treat data for serious infections and malignancies were abstracted. Published information from the trials was supplemented by direct contact between principal investigators and industry sponsors.
DATA SYNTHESIS: We calculated a pooled odds ratio (Mantel-Haenszel methods with a continuity correction designed for sparse data) for malignancies and serious infections (infection that requires antimicrobial therapy and/or hospitalization) in anti-TNF-treated patients vs placebo patients. We estimated effects for high and low doses separately. The pooled odds ratio for malignancy was 3.3 (95% confidence interval [CI], 1.2-9.1) and for serious infection was 2.0 (95% CI, 1.3-3.1). Malignancies were significantly more common in patients treated with higher doses compared with patients who received lower doses of anti-TNF antibodies. For patients treated with anti-TNF antibodies in the included trials, the number needed to harm was 154 (95% CI, 91-500) for 1 additional malignancy within a treatment period of 6 to 12 months. For serious infections, the number needed to harm was 59 (95% CI, 39-125) within a treatment period of 3 to 12 months.
CONCLUSIONS: There is evidence of an increased risk of serious infections and a dose-dependent increased risk of malignancies in patients with rheumatoid arthritis treated with anti-TNF antibody therapy. The formal meta-analysis with pooled sparse adverse events data from randomized controlled trials serves as a tool to assess harmful drug effects.
Authors:
Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Related Documents :
12455839 - Foraging enrichment for stabled horses: effects on behaviour and selection.
20826029 - A prospective, randomized, multi-center trial to investigate actovegin in prevention an...
20536689 - Multi-centre assessment of mycotic rhinosinusitis in dogs: a retrospective study of ini...
11840709 - A complication conference for internal quality control at the neurosurgical department ...
17943809 - Azathioprine for multiple sclerosis.
15495129 - Antifibrinolytic drugs for acute traumatic injury.
1607519 - Intermediate-term outcome after pulmonary balloon valvuloplasty: comparison with a matc...
24136239 - Photodynamic therapy for management of cervical intraepithelial neoplasia ii and iii in...
12440629 - Management of pharyngoesophageal (zenker's) diverticulum: which technique?
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  JAMA : the journal of the American Medical Association     Volume:  295     ISSN:  1538-3598     ISO Abbreviation:  JAMA     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-17     Completed Date:  2006-05-23     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2275-85     Citation Subset:  AIM; IM    
Affiliation:
Division of Rheumatology and Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA. bongartz.tim@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / adverse effects,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Humans
Immunologic Factors / adverse effects,  therapeutic use*
Infection / epidemiology
Neoplasms / epidemiology
Randomized Controlled Trials as Topic
Risk
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Immunologic Factors; 0/Tumor Necrosis Factor-alpha; 0/infliximab; FYS6T7F842/adalimumab
Comments/Corrections
Comment In:
ACP J Club. 2006 Nov-Dec;145(3):65   [PMID:  17080977 ]
JAMA. 2006 Nov 8;296(18):2201; author reply 2203-4   [PMID:  17090761 ]
JAMA. 2006 Nov 8;296(18):2205   [PMID:  17090765 ]
JAMA. 2006 Nov 8;296(18):2201-2; author reply 2203-4   [PMID:  17090760 ]
JAMA. 2006 Nov 8;296(18):2203; author reply 2203-4   [PMID:  17090763 ]
JAMA. 2006 Nov 8;296(18):2202; author reply 2203-4   [PMID:  17090762 ]
Arch Dermatol. 2007 Mar;143(3):405-6   [PMID:  17372107 ]
Erratum In:
JAMA. 2006 Jun 7;295(21):2482

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit or...
Next Document:  Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast ...